Silence Therapeutics PLC Capital Markets Day (3663W)

TIDMSLN

RNS Number : 3663W

Silence Therapeutics PLC

14 November 2017

Silence Therapeutics' 2017 Capital Markets Day

14 November 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will today host a Capital Markets Day for analysts, investors and media from 2:15pm to 6:00pm GMT at ME London Hotel, Strand, London WC2R 1HA.

At the meeting, Silence will provide an update on its proprietary and innovative RNAi technology platform and on selected pipeline programmes (Iron Overload Disorders and Alcohol Use Disorder), as well as an overview of the Company's strategy and operational setup. Speakers from the Company will include:

   --     Dr Annalisa Jenkins, Board Chair 
   --     Ali Mortazavi, Chief Executive Officer 
   --     Dr Torsten Hoffmann, Chief Operating Officer 
   --     Dr Dmitry Samarsky, Chief Scientific Officer 
   --     Dr Ulrich Zügel, Head of Preclinical Drug Discovery 

No material new information will be provided during the presentations.

Following the Company presentations, Silence will host a panel discussion on genomics, big data and ways to harness outcomes with genetic medicines such as RNAi. Five key opinion leaders from relevant fields will form the panel.

All presentation materials will be available on the company website at www.silence-therapeutics.com shortly after the event has concluded.

Enquiries:

 
 Silence Therapeutics plc                Tel: +44 (0)20 
  Ali Mortazavi, Chief Executive          3457 6900 
  Officer 
  David Ellam, Chief Financial Officer 
 
 Peel Hunt LLP (Nominated Adviser        Tel: +44 (0)20 
  and Broker)                             7418 8900 
  James Steel/Oliver Jackson 
 Media Enquiries:                        Tel: +44 (0) 
  FTI Consulting                          20 3727 1000 
  Simon Conway/Brett Pollard/Stephanie 
  Cuthbert 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAKFDFSNXFFF

(END) Dow Jones Newswires

November 14, 2017 02:00 ET (07:00 GMT)